Literature DB >> 20020334

Case reports: subtrochanteric femoral stress fractures after prolonged alendronate therapy.

Katerina Cermak1, Felix Shumelinsky, Jean Alexiou, Michael J Gebhart.   

Abstract

BACKGROUND: Alendronate is known for its ability to reduce bone loss in osteoporotic and osseous metastatic conditions. Its long-term effects remain unclear although several reports describe cases of proximal femur stress fractures associated with long-term alendronate use. CASE DESCRIPTION: We report the cases of four women who sustained low-energy subtrochanteric or femoral shaft stress fractures while being on alendronate therapy for more than 5 years. All radiographs showed typical patterns consisting of a transverse fracture line with external cortical bone reaction and medial cortical spike. Alendronate discontinuation along with nonoperative treatment was sufficient for one patient, whereas surgical stabilization was required in three patients. LITERATURE REVIEW: The side effects of alendronate therapy include osteonecrosis of the jaw, esophageal irritation, and musculoskeletal pain. Several cases of insufficiency femoral fractures associated with prolonged alendronate use have been reported. Their radiographic pattern and clinical presentation are consistent with our observations. Although various hypotheses have been suggested, the physiopathogenesis of these stress fractures is not completely understood. PURPOSES AND CLINICAL RELEVANCE: Although bisphosphonates play an important role in preventing pathologic fractures in patients with cancer, these subtrochanteric stress fractures associated with prolonged use of alendronate should not be ignored.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20020334      PMCID: PMC2881993          DOI: 10.1007/s11999-009-1192-0

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  28 in total

1.  A displaced subtrochanteric stress fracture in a young amenorrheic athlete.

Authors:  C F Leinberry; R B McShane; W G Stewart; E L Hume
Journal:  Am J Sports Med       Date:  1992 Jul-Aug       Impact factor: 6.202

2.  Long-term safety of bisphosphonates.

Authors:  Susan M Ott
Journal:  J Clin Endocrinol Metab       Date:  2005-03       Impact factor: 5.958

3.  Severely suppressed bone turnover: a potential complication of alendronate therapy.

Authors:  Clarita V Odvina; Joseph E Zerwekh; D Sudhaker Rao; Naim Maalouf; Frank A Gottschalk; Charles Y C Pak
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

4.  Subtrochanteric stress fractures in runners.

Authors:  J E Butler; S L Brown; B G McConnell
Journal:  Am J Sports Med       Date:  1982 Jul-Aug       Impact factor: 6.202

5.  Bone fragility of the peripheral skeleton during fluoride therapy for osteoporosis.

Authors:  C M Schnitzler; J R Wing; K A Gear; H J Robson
Journal:  Clin Orthop Relat Res       Date:  1990-12       Impact factor: 4.176

6.  Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group.

Authors:  D M Black; S R Cummings; D B Karpf; J A Cauley; D E Thompson; M C Nevitt; D C Bauer; H K Genant; W L Haskell; R Marcus; S M Ott; J C Torner; S A Quandt; T F Reiss; K E Ensrud
Journal:  Lancet       Date:  1996-12-07       Impact factor: 79.321

7.  Hip pain in a case of hypophosphatemic osteomalacia.

Authors:  Justin Esterberg; Rida A Kassim; John Redmon; James Coad; George S Macari; Khaled J Saleh
Journal:  Am J Orthop (Belle Mead NJ)       Date:  2003-09

8.  Effects of differences in mineralization on the mechanical properties of bone.

Authors:  J D Currey
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1984-02-13       Impact factor: 6.237

9.  Stress fractures of the lower limbs in osteoporotic patients treated with fluoride.

Authors:  P Orcel; M C de Vernejoul; A Prier; L Miravet; D Kuntz; G Kaplan
Journal:  J Bone Miner Res       Date:  1990-03       Impact factor: 6.741

10.  Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.

Authors:  Kristine E Ensrud; Elizabeth L Barrett-Connor; Ann Schwartz; Arthur C Santora; Douglas C Bauer; Shailaja Suryawanshi; Adrianne Feldstein; William L Haskell; Marc C Hochberg; James C Torner; Antonio Lombardi; Dennis M Black
Journal:  J Bone Miner Res       Date:  2004-03-29       Impact factor: 6.741

View more
  12 in total

1.  Bisphosphonate-associated femur fractures have high complication rates with operative fixation.

Authors:  Mark L Prasarn; Jaimo Ahn; David L Helfet; Joseph M Lane; Dean G Lorich
Journal:  Clin Orthop Relat Res       Date:  2012-06-06       Impact factor: 4.176

Review 2.  The role of bisphosphonates in multiple myeloma: mechanisms, side effects, and the future.

Authors:  Samantha Pozzi; Noopur Raje
Journal:  Oncologist       Date:  2011-04-14

3.  Low-energy femoral shaft fractures after long-term alendronate therapy: report of seven cases.

Authors:  Efstathios G Ballas; Andreas F Mavrogenis; Eirineos Karamanis; Zinon T Kokkalis; Evanthia Mitsiokapa; Demetrios Koulalis; Demetrios Mastrokalos; Panayiotis J Papagelopoulos
Journal:  Eur J Orthop Surg Traumatol       Date:  2014-03-28

4.  Femoral stress fractures associated with long-term bisphosphonate treatment.

Authors:  William G Ward; Christina J Carter; Scott C Wilson; Cynthia L Emory
Journal:  Clin Orthop Relat Res       Date:  2012-03       Impact factor: 4.176

5.  Simultaneous, bilateral, complete atypical femoral fractures after long-term alendronate use.

Authors:  Mark Higgins; Sam Morgan-John; Sachin Badhe
Journal:  J Orthop       Date:  2016-08-12

6.  Management strategy for symptomatic bisphosphonate-associated incomplete atypical femoral fractures.

Authors:  Anas Saleh; Vishal V Hegde; Anish G Potty; Robert Schneider; Charles N Cornell; Joseph M Lane
Journal:  HSS J       Date:  2012-05-02

7.  Applying low-intensity pulsed ultrasounds (LIPUS) to a zoledronate-associated atypical femoral shaft fracture without cessation of zoledronate therapy for 3 years follow up: a case report.

Authors:  Shoutaro Arakawa; Mitsuru Saito; Makoto Kubota; Hidehiko Suzuki; Shigeki Tsuchida; Kurando Hashimoto; Keishi Marumo
Journal:  Clin Cases Miner Bone Metab       Date:  2015-12-29

8.  Propagation of bisphosphonate-related femoral stress fractures despite femoral nailing: a cautionary tale from 2 cases.

Authors:  Christian Fang; Jackie Yee-Man Chau; Siu-Bon Woo; Tak-Wing Lau; Kenny Kwan; Frankie Leung
Journal:  Geriatr Orthop Surg Rehabil       Date:  2014-03

Review 9.  Subtrochanteric fractures after long-term treatment with bisphosphonates: a European Society on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis, and International Osteoporosis Foundation Working Group Report.

Authors:  R Rizzoli; K Akesson; M Bouxsein; J A Kanis; N Napoli; S Papapoulos; J-Y Reginster; C Cooper
Journal:  Osteoporos Int       Date:  2010-11-18       Impact factor: 4.507

10.  5-Androstene-3β,7β,17β-triol (β-AET) slows thermal injury induced osteopenia in mice: relation to aging and osteoporosis.

Authors:  Ajay K Malik; Sophia Khaldoyanidi; Dominick L Auci; Scott C Miller; Clarence N Ahlem; Christopher L Reading; Theodore Page; James M Frincke
Journal:  PLoS One       Date:  2010-10-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.